The analysis of plasma samples from HIV-1/HCV mono- and coinfected individuals by quantitative proteomics is an efficient strategy to investigate changes in protein abundances and to characterize the proteins that are the effectors of cellular functions involved in viral pathogenesis. In this study, the infected and healthy plasma samples (in triplicate) were treated with ProteoMiner beads to equalize protein concentrations and subjected to 4-plex iTRAQ labeling and liquid chromatography/mass spectrometry (LC-MS/MS) analysis. A total of 70 proteins were identified with high confidence in the triplicate analysis of plasma proteins and 65% of the proteins were found to be common among the three replicates. Apolipoproteins and complement proteins are the two major classes of proteins that exhibited differential regulation. The results of quantitative analysis revealed that APOA2, APOC2, APOE, C3, HRG proteins were upregulated in the plasma of all the three HIV-1 mono-, HCV mono-, and coinfected patient samples compared to healthy control samples. Ingenuity pathway analysis (IPA) of the upregulated proteins revealed that they are implicated in the hepatic lipid metabolism, inflammation, and acute-phase response signaling pathways. Thus, we identified several differentially regulated proteins in HIV-1/HCV mono and coinfected plasma samples that may be potential biomarkers for liver disease.
Get full access to this article
View all access options for this article.
References
1.
AttallahA.M., ZahranF., IsmailH., OmranM.M., El-DosokyI., ShihaG.E.2007. Immunochemical identification and detection of serum fibronectin in liver fibrosis patients with chronic hepatitis C. J Immunoassay Immunochem, 28:331–342.
2.
BaetenJ.M., WenerM.H., BanksonD.D., LavreysL., RichardsonB.A., MandaliyaK.et al.2006. HIV-1 infection alters the retinol-binding protein:transthyretin ratio even in the absence of the acute phase response. J Nutr, 136:1624–1629.
3.
BardJ.M., LassalleR., CapeauJ., Bach-NgohouK., Nazih-SandersonF., RemyG.et al.2006. Association of apolipoproteins C3 and E with metabolic changes in HIV-infected adults treated with a protease-inhibitor-containing antiretroviral therapy. Antivir Ther, 11:361–370.
4.
BruderC., HagleitnerM., DarlingtonG., MohsenipourI., WurznerR., HollmullerI.et al.2004. HIV-1 induces complement factor C3 synthesis in astrocytes and neurons by modulation of promoter activity. Mol Immunol, 40:949–961.
5.
BurgenerA., BoutilierJ., WachihiC., KimaniJ., CarpenterM., WestmacottG.et al.2008. Identification of differentially expressed proteins in the cervical mucosa of HIV-1-resistant sex workers. J Proteome Res, 7:4446–4454.
6.
ChenD.S., SungJ.L., SheuJ.C., LaiM.Y., HowS.W., HsuH.C.et al.1984. Serum alpha-fetoprotein in the early stage of human hepatocellular carcinoma. Gastroenterology, 86:1404–1409.
7.
CheungK.J., TillemanK., DeforceD., ColleI., Van VlierbergheH.2009. The HCV serum proteome: a search for fibrosis protein markers. J Viral Hepat, 16:418–429.
Dumestre-PerardC., PonardD., DrouetC., LeroyV., ZarskiJ.P., DutertreN.et al.2002. Complement C4 monitoring in the follow-up of chronic hepatitis C treatment. Clin Exp Immunol, 127:131–136.
10.
DwivediR.C., KrokhinO.V., CortensJ.P., WilkinsJ.A.2010. Assessment of the reproducibility of random hexapeptide peptide library-based protein normalization. J Proteome Res, 9:1144–1149.
11.
ErnoultE., BourreauA., GamelinE., GuetteC.2010. A proteomic approach for plasma biomarker discovery with iTRAQ labelling and OFFGEL fractionation. J Biomed Biotechnol 2010, 927917.
12.
FranciscusA., HighleymanL.2007. HIV/HCV Coinfection. Hepatitis C Support, pp. Factsheet: 2. HCVadvocate.org: San Francisco, CA.
13.
GangadharanB., AntrobusR., DwekR.A., ZitzmannN.2007. Novel serum biomarker candidates for liver fibrosis in hepatitis C patients. Clin Chem, 53:1792–1799.
GonzalezS.A., TalalA.H.2003. Hepatitis C virus in human immunodeficiency virus-infected individuals: an emerging comorbidity with significant implications. Semin Liver Dis, 23:149–166.
16.
GuerrierL., RighettiP.G., BoschettiE.2008. Reduction of dynamic protein concentration range of biological extracts for the discovery of low-abundance proteins by means of hexapeptide ligand library. Nat Protoc, 3:883–890.
HarveyS.B., ZhangY., Wilson-GradyJ., MonkkonenT., NelsestuenG.L., KasthuriR.S.et al.2009. O-glycoside biomarker of apolipoprotein C3: responsiveness to obesity, bariatric surgery, and therapy with metformin, to chronic or severe liver disease and to mortality in severe sepsis and graft vs host disease. J Proteome Res, 8:603–612.
19.
HeckmannJ.G., KayserC., HeussD., MangerB., BlumH.E., NeundorferB.1999. Neurological manifestations of chronic hepatitis C. J Neurol, 246:486–491.
20.
Imbert-BismutF., RatziuV., PieroniL., CharoltteF., BenhamouY., PoynardT.2001. Biochemical markers of liver fibrosis in patients with hepatitis C virus infection: a prospective study. Lancet, 357:1069–1075.
21.
KeidelE.M., RibitschD., LottspeichF.2010. Equalizer technology—equal rights for disparate beads. Proteomics, 10:2089–2098.
22.
KimS.S., KimM.H., ShinB.K., NaH.J., ChoiJ.Y., KeeM.K.et al.2007. Different isoforms of apolipoprotein AI present heterologous post-translational expression in HIV infected patients. J Proteome Res, 6:180–184.
23.
KoikeK.2005. Hepatitis C as a metabolic disease: implication for the pathogenesis of NASH. Hepatol Res, 33:145–150.
24.
KramerJ.R., GiordanoT.P., SouchekJ., RichardsonP., HwangL.Y., El-SeragH.B.2005. The effect of HIV coinfection on the risk of cirrhosis and hepatocellular carcinoma in U.S. veterans with hepatitis C. Am J Gastroenterol, 100:56–63.
25.
KuhlmannI., MinihaneA.M., HuebbeP., NebelA., RimbachG.2010. Apolipoprotein E genotype and hepatitis C, HIV and herpes simplex disease risk: a literature review. Lipids Health Dis, 9:8.
26.
KulkarniY.M., SuarezV., KlinkeD.J.2nd. 2010. Inferring predominant pathways in cellular models of breast cancer using limited sample proteomic profiling. BMC Cancer, 10:291.
27.
LeeI.N., ChenC.H., SheuJ.C., LeeH.S., HuangG.T., ChenD.S.et al.2006. Identification of complement C3a as a candidate biomarker in human chronic hepatitis C and HCV-related hepatocellular carcinoma using a proteomics approach. Proteomics, 6:2865–2873.
28.
LiuL., ZengM., StamlerJ.S.1999. Hemoglobin induction in mouse macrophages. Proc Natl Acad Sci USA, 96:6643–6647.
29.
Luciano-MontalvoC., CiborowskiP., DuanF., GendelmanH.E., MelendezL.M.2008. Proteomic analyses associate cystatin B with restricted HIV-1 replication in placental macrophages. Placenta, 29:1016–1023.
30.
MartinI., DuboisM.C., SaermarkT., RuysschaertJ.M.1992. Apolipoprotein A-1 interacts with the N-terminal fusogenic domains of SIV (simian immunodeficiency virus) GP32 and HIV (human immunodeficiency virus) GP41: implications in viral entry. Biochem Biophys Res Commun, 186:95–101.
31.
MasV.R., MalufD.G., ArcherK.J., YanekK., BornsteinK., FisherR.A.2009. Proteomic analysis of HCV cirrhosis and HCV-induced HCC: identifying biomarkers for monitoring HCV-cirrhotic patients awaiting liver transplantation. Transplantation, 87:143–152.
32.
MatthewsG.V., DoreG.J.2008. HIV and hepatitis C coinfection. J Gastroenterol Hepatol, 23:1000–1008.
33.
MerchanteN., Giron-GonzalezJ.A., Gonzalez-SerranoM., Torre-CisnerosJ., Garcia-GarciaJ.A., ArizcorretaA.et al.2006. Survival and prognostic factors of HIV-infected patients with HCV-related end-stage liver disease. AIDS, 20:49–57.
34.
MeunierJ.C., RussellR.S., EngleR.E., FaulkK.N., PurcellR.H., EmersonS.U.2008. Apolipoprotein c1 association with hepatitis C virus. J Virol, 82:9647–9656.
35.
OstapowiczG., WatsonK.J., LocarniniS.A., DesmondP.V.1998. Role of alcohol in the progression of liver disease caused by hepatitis C virus infection. Hepatology, 27:1730–1735.
PinedaJ.A., Romero-GomezM., Diaz-GarciaF., Giron-GonzalezJ.A., MonteroJ.L., Torre-CisnerosJ.et al.2005. HIV coinfection shortens the survival of patients with hepatitis C virus-related decompensated cirrhosis. Hepatology, 41:779–789.
38.
PinterC., SiccardiA.G., LonghiR., ClivioA.1995. Direct interaction of complement factor H with the C1 domain of HIV type 1 glycoprotein 120. AIDS Res Hum Retroviruses, 11:577–588.
39.
RahmanS., ConnollyJ.E., ManuelS.L., ChehimiJ., MontanerL.J., JainP.2011. Unique cytokine/chemokine signatures for HIV-1 and HCV mono-infection versus co-infection as determined by the Luminex® analyses. J Clin Cell Immunol(in press).
40.
RasheedS., YanJ.S., HussainA., LaiB.2009. Proteomic characterization of HIV-modulated membrane receptors, kinases and signaling proteins involved in novel angiogenic pathways. J Transl Med, 7:75.
41.
RoeB., CoughlanS., HassanJ., GroganA., FarrellG., NorrisS.et al.2007. Elevated serum levels of interferon- gamma -inducible protein-10 in patients coinfected with hepatitis C virus and HIV. J Infect Dis, 196:1053–1057.
42.
RosenbergW.M., VoelkerM., ThielR., BeckaM., BurtA., SchuppanD.et al.2004. Serum markers detect the presence of liver fibrosis: a cohort study. Gastroenterology, 127:1704–1713.
43.
RossP.L., HuangY.N., MarcheseJ.N., WilliamsonB., ParkerK., HattanS.et al.2004. Multiplexed protein quantitation in Saccharomyces cerevisiae using amine-reactive isobaric tagging reagents. Mol Cell Proteomics, 3:1154–1169.
SumidaY., NakashimaT., YohT., NakajimaY., IshikawaH., MitsuyoshiH.et al.2000. Serum thioredoxin levels as an indicator of oxidative stress in patients with hepatitis C virus infection. J Hepatol, 33:616–622.
46.
SuzmanD.L., McLaughlinM., HuZ., KleinerD.E., WoodB., LempickiR.A.et al.2008. Identification of novel markers for liver fibrosis in HIV/hepatitis C virus coinfected individuals using genomics-based approach. AIDS, 22:1433–1439.
47.
Tacnet-DelormeP., BoyerV., ThielensN.M., HernandezJ.F., BallyI., SimR.B.et al.1999. In vitro analysis of complement-dependent HIV-1 cell infection using a model system. J Immunol, 162:4088–4093.
48.
ToulonP.1998. [Hemostasis and human immunodeficiency virus (HIV) infection]Ann Biol Clin (Paris), 56:153–160.
49.
WiederinJ., RozekW., DuanF., CiborowskiP.2009. Biomarkers of HIV-1 associated dementia: proteomic investigation of sera. Proteome Sci, 7:8.
50.
YeH., SunL., HuangX., ZhangP., ZhaoX.2010. A proteomic approach for plasma biomarker discovery with 8-plex iTRAQ labeling and SCX-LC-MS/MS. Mol Cell Biochem, 343:91–99.
51.
ZhangL., JiaX., ZhangX., SunJ., PengX., QiT.et al.2010. Proteomic analysis of PBMCs: characterization of potential HIV-associated proteins. Proteome Sci, 8:12.
Supplementary Material
Please find the following supplemental material available below.
For Open Access articles published under a Creative Commons License, all supplemental material carries the same license as the article it is associated with.
For non-Open Access articles published, all supplemental material carries a non-exclusive license, and permission requests for re-use of supplemental material or any part of supplemental material shall be sent directly to the copyright owner as specified in the copyright notice associated with the article.
